60 Million Images, One European Cancer Database

EUCAIM aims to pool 60 million anonymized cancer scans from over 100,000 patients across 15 EU nations by 2027.

12 Aug 2026

Europe's effort to pool cancer imaging data for medical research is approaching a significant milestone, with a federated platform on track to gather 60mn anonymised scans from more than 100,000 patients by the end of 2026.

Backing the initiative, known as Cancer Image Europe, is €36mn in funding from the EU's Digital Europe programme. More than 30 data providers across 15 member states are already contributing to the system, which operates under the wider EUCAIM project.

Rather than centralising patient records in one location, the platform uses a federated model: data stays with the hospitals and institutions that hold it, while approved researchers can still use the full dataset to train and test artificial intelligence tools. Proponents say this addresses long-standing privacy concerns that have slowed similar efforts elsewhere.

Scale is central to the dataset's appeal. A larger pool of imaging data allows AI systems to be tested against more varied cases, which developers say should improve accuracy in detecting cancer earlier and tailoring treatment to individual patients.

Underlining their commitment to the project, the European Commission and member states signed a declaration, "Towards Unleashing Access to at least 60 Million Cancer Medical Images in the European Union by 2027," suggesting the initiative is intended to continue well past its current build-out phase.

Clinical standards for the images collected have been shaped with help from the European Society of Radiology, a step organisers say is necessary to ensure the data is consistent enough for AI systems to use reliably.

For companies developing diagnostic AI tools, the platform addresses a persistent obstacle: finding enough varied, high-quality, and legally compliant data to train their systems.

Access to a dataset of this size could shorten the path from prototype to clinical use, though developers will still need to meet regulatory approval requirements before tools reach hospitals.

Whether the platform meets its 2027 target will depend on continued participation from data providers and sustained funding. The project's backers frame it as a step toward positioning Europe as a leading centre for AI-assisted cancer diagnosis, though the practical impact on patient outcomes will only become clear as more tools built on the dataset move into clinical settings.